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Chemical Conjugation of rituximab monoclonal antibody and asparaginase for assessment of 
cytotoxicity on ALL cehhs 
Abstract 
Introduction: Antibody-drug conjugates (ADCs) are emerging classes of antineoplastic agents 
ccrrently administered to cancer patients. Of ADCs, antibody-enzyme conjugate (AEC) is finding 
increasing use as a novel ADC. 
Methods: Here the conjugate of L-asparaginase (ASNase) and rituximab (Ritux) monoclonal 
antibody was synthesized using 3,3-Dithio-bis-(sulfosuccinimidyl) propionate linker. The 
resultant conhugate and its cytotoxic effects were demonstrated by dynamic light scattering 
(DLS) and optical microscopy. 
 
Results: DLS results showed that free asparaginsse and rituximab molecules respectively have 
the mean diameter of 3.4 and 10.2 nm. Upon conjugation with DSP, the average diameter of 
the conjugate increased significantly (13.6 nm). Moreover, zeta potential analysis proved the 
conjugation event; because zeta potential of free rituximab molecules (-3.7±3 mV) increased 
dramatically after conjugation with asparaginase molecules (+24±4 mV).  Treatment of blood 
samples from acute lymphoblastic leukemia (ALL) patientswith the conjugate resulted in the 
apoptosis but no necrosis of ALL cells, while normal blood cells were damaged slightly. 
Apoptosis and necrosis events and chromatin condensation images taken by optical 
microscopy represent that rituximab-asparaginase conjugate affects ALL cells specifically, and 
only the cells that overexpress CD20 are damaged. 
 
Conclusion: This new method of conjucation can be used for efficient conjugation of 
monoclonal antibodies with enzyme and protein- based therapeutics. Howere, animal studies 
are recommended for finding effective dose and side effects. 
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